A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
Hosted on MSN14h
Ozempic Could Help Curb AlcoholismUse of a second drug in the same class of GLP-1 medications, liraglutide (Victoza), was linked to a 28% reduction in ...
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...
A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...
Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Depending on the medication, the effects can last for a minimum of 24 hours to a few weeks. Examples include dulaglutide, ...
About The Study: Among patients with alcohol use disorder (AUD) and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback